Collaboration Models
Co-development

For targets of mutual interest, we and our partners divide responsibilities between discovery-to-PCC development and PCC-to-BLA development. By combining complementary strengths, we accelerate project execution and bring effective, safe medicines to patients sooner.

Technology Transfer & Licensing

Hit antibodies and established PCC molecules can be licensed to partners through technology transfer or patent licensing, with the partner taking responsibility for subsequent development.

Project Incubation

Aiming at innovative biologics in clinical development, and targeting first-in-class and best-in-class products for specific disease areas, Symray Biopharma welcomes like-minded partners to co-develop and jointly incubate projects through joint ventures.

Partners